论文部分内容阅读
目的:研究参芪胶囊治疗多囊卵巢综合征患者的临床效果。方法:纳入2014年2月至2015年7月我院收治的多囊卵巢综合征患者60例,按随机数字表法分为观察组及对照组各30例,观察组给予参芪胶囊治疗,对照组患者给予常规西药进行治疗,记录并分析治疗后两组患者相关指标的对比情况。结果:观察组治疗后高雄激素值为(15.23±2.61)nmol/L明显优于对照组(20.06±2.87)nmol/L;观察组治疗后LH、FSH、T水平分别为4.52±0.49IU/ml、6.52±0.64IU/ml、1.85±0.31nmol/L,均明显优于对照组5.45±0.61IU/ml、9.67±1.21IU/ml、2.40±0.35nmol/L;观察组治疗后卵巢体积和卵巢间质面积分别为6.91±0.24、1.41±0.05cm3,均明显优于对照组7.59±0.35、1.70±0.08cm3;观察组治疗后临床总显效率达66.67%,明显高于对照组36.67%。结论:参芪胶囊治疗多囊卵巢综合征患者的临床效果优于常规西药,且无明显副作用,值得临床进一步研究和应用。
Objective: To study the clinical effect of Shenqi capsule in the treatment of patients with polycystic ovary syndrome. Methods: Sixty patients with polycystic ovary syndrome admitted to our hospital from February 2014 to July 2015 were randomly divided into observation group (30 cases) and control group (30 cases). The observation group was treated with Shenqi Capsule. The control group Group of patients given conventional Western medicine for treatment, record and analyze the comparison of the two groups of patients after treatment indicators. Results: The value of high androgen in the observation group was (15.23 ± 2.61) nmol / L, which was significantly higher than that in the control group (20.06 ± 2.87) nmol / L. After treatment, the levels of LH, FSH and T in the observation group were 4.52 ± 0.49IU / ml , 6.52 ± 0.64IU / ml, 1.85 ± 0.31nmol / L, respectively, which were significantly better than the control group 5.45 ± 0.61IU / ml, 9.67 ± 1.21IU / ml, 2.40 ± 0.35nmol / Interstitial area were 6.91 ± 0.24,1.41 ± 0.05cm3, were significantly better than the control group 7.59 ± 0.35,1.70 ± 0.08cm3; observation group after treatment, the total clinical effective rate was 66.67%, significantly higher than the control group 36.67%. Conclusion: Shenqi capsule in the treatment of patients with polycystic ovary syndrome clinical effect is superior to conventional western medicine, and no obvious side effects, it is worth further clinical study and application.